Ulcerative Colitis in the Modern Era: Pathogenesis, Evolving Therapies and Future Directions

Year 2026, Volume: 46 Issue: 1 , 83 - 98 , 01.03.2026

Nisha Shri Chengamaraju , Shaheda Shaheda Suvarchala Reddy Gangaraju Mudunuri Rohini Rasamallu

https://izlik.org/JA36PH56BD

Abstract

Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation of the colon, usually starting in the rectum. Its complex pathogenesis arises from genetic predisposition, immune dysregulation, epithelial barrier defects and gut microbiota imbalance. Clinically, UC presents with relapsing-remitting episodes of bloody diarrhea, abdominal pain, and rectal urgency. Diagnosis requires a comprehensive approach using clinical evaluation, endoscopy, histopathology and imaging. Treatment is guided by disease severity and extent. 5-aminosalicylic acid (5-ASA) agents such as mesalazine, olsalazine and balsalazide remain first-line options for mild to moderate UC. Corticosteroids are effective but unsuitable for long-term use due to adverse effects. Immunomodulators like azathioprine and methotrexate support maintenance therapy and enhance biologic durability. Biologics including anti-TNF therapies, anti-integrin antibodies and IL-12/23 inhibitors have transformed management of moderate to severe UC. New oral small molecules such as JAK inhibitors and S1P receptor modulators further expand available options. Emerging interventions like granulocyte-monocyte apheresis, fecal microbiota transplantation and microbiota-based therapies (probiotics, postbiotics, symbiotics) offer personalized approaches. The future of UC management lies in precision medicine, incorporating biomarkers, pharmacogenomics and individualized algorithms to optimize outcomes and improve patient quality of life.

Keywords

Ulcerative colitis , Gut microbiota , Granulocyte-monocyte apheresis , Fecal microbiota transplantation (FMT).

References

• 1. Pasvol TJ, Horsfall L, Bloom S, et al. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020;10:e036584. https://doi.org/10.1136/bmjopen-2019-036584
• 2. Landeira M, Markert M, Guedes S, Balijepalli C, et al. Global epidemiology of Ulcerative Colitis: A systematic literature review from 2014 – 2025. Journal of Crohn’s and Colitis. 2026;20(1):i2805. https://doi.org/10.1093/ecco-jcc/jjaf231.1367
• 3. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74. https://www.nature.com/articles/s41572-020-0205-x
• 4. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106. https://doi.org/10.1136/gutjnl-2019-318484
• 5. Shah SC, Itzkowitz SH. Reappraising risk factors for inflammatory bowel disease-associated neoplasia: implications for colonoscopic surveillance in IBD. J Crohns Colitis. 2020;14:1172–7. https://doi.org/10.1093/ecco-jcc/jjaa040
• 6. Høivik ML, Moum B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62:368–75. https://doi.org/10.1136/gutjnl-2012-302311
• 7. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356–63. https://doi.org/10.1002/ibd.22839
• 8. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–38. https://doi.org/10.1038/ajg.2015.233
• 9. Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573–83. https://doi.org/10.1002/ibd.21815
• 10. Roda G, Narula N, Pinotti R, et al. Systematic review with meta-analysis: Proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther. 2017;45:1481–92. https://doi.org/10.1111/apt.14063
• 11. Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: A systematic review. Clin Gastroenterol Hepatol. 2018;16:343–56.e3. https://doi.org/10.1016/j.cgh.2017.06.016
• 12. Eriksson C, Cao Y, Rundquist S, et al. Changes in medical management and colectomy rates: A population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963–2010. Aliment Pharmacol Ther. 2017;46:748–57. https://doi.org/10.1111/apt.14268
• 13. Darr U, Khan N. Treat to target in inflammatory bowel disease: An updated review of literature. Curr Treat Options Gastroenterol. 2017;15:116–25. https://link.springer.com/article/10.1007/s11938-017-0130-6
• 14. Peyrin-Biroulet L, Germain A, Patel AS, et al. Systematic review: Outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44:807–16. https://doi.org/10.1111/apt.13763
• 15. Feuerstein JD, Cheifetz AS. Ulcerative colitis: Epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553–63. https://doi.org/10.1016/j.mayocp.2014.07.002
• 16. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: Results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–35. https://doi.org/10.1038/ajg.2012.127
• 17. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis.2017;11:769–84.https://doi.org/10.1093/ecco-jcc/jjx009
• 18. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Clin Exp Gastroenterol. 2019;14:14. https://doi.org/10.1016/j.disamonth.2019.02.004
• 19. Terry R, Chintanaboina J, Patel D, et al. Expression of WIF-1 in inflammatory bowel disease. Histol Histopathol. 2019;34(2):149–57. https://doi.org/10.14670/hh-18-031
• 20. Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, et al. Caspase recruitment domain (CARD) family are increased during active inflammation in IBD. J Inflamm (Lond). 2018;15:13. https://doi.org/10.1186/s12950-018-0189-4
• 21. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9. https://doi.org/10.1053/j.gastro.2008.04.023
• 22. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis: adjunct or alternative to drug therapy? J Clin Apher. 2005;20:171–84. https://doi.org/10.1002/jca.20046
• 23. Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther Apher Dial. 2003;7:44–7. https://doi.org/10.1046/j.1526-0968.2003.00009.x
• 24. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis. Dig Dis Sci. 2002;47:1334–41. https://doi.org/10.1023/a:1015330816364
• 25. Grisham MB, Yamada T. Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann N Y Acad Sci. 1992;664:103–15. https://doi.org/10.1111/j.1749-6632.1992.tb39753.x
• 26. Paramsothy S, Nielsen S, Kamm MA, et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with UC. Gastroenterology. 2019;156(5):1440–54. https://doi.org/10.1053/j.gastro.2018.12.001
• 27. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(Suppl 1):S15–21. https://doi.org/10.1097/01.MIB.0000195387.26892.22
• 28. Hanai H, Takeda Y, Eberhardson M, et al. The mode of actions of Adacolumn therapeutic leucocytapheresis: concise review. Clin Exp Immunol. 2011;163:50–8. https://doi.org/10.1111/j.1365-2249.2010.04279.x
• 29. Kashiwagi N, Nakano M, Saniabadi AR, et al. Anti-inflammatory effect of granulocyte and monocyte adsorption apheresis in rabbit arthritis model. Inflammation. 2002;26:199–205. https://link.springer.com/article/10.1023/A:1016523914161
• 30. Kuijpers TW, Tool AT, van der Schoot CE, et al. Membrane surface antigen expression on neutrophils. Blood. 1991;78:1105–11. https://doi.org/10.1182/blood.V78.4.1105.1105
• 31. Waitz G, Petermann S, Liebe S, et al. Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis. Dig Dis Sci. 2008;53:2507–15. https://link.springer.com/article/10.1007/s10620-007-0168-8
• 32. Cuadrado E. Granulocyte/monocyte apheresis as immunotherapeutic tool: immune modulation. Autoimmun Rev. 2009;8:292–6. https://doi.org/10.1016/j.autrev.2008.09.001
• 33. Cuadrado E, Alonso M, de Juan MD, et al. Regulatory T cells in IBD patients treated with Adacolumn granulocytapheresis. World J Gastroenterol. 2008;14:1521–7. https://doi.org/10.3748/wjg.14.1521
• 34. Toya Y, Chiba T, Mizutani T, et al. Effect of granulocyte and monocyte apheresis on cytokine levels. Cytokine. 2013;62:146–50. https://doi.org/10.1016/j.cyto.2013.01.019
• 35. Hanai H. Positions of selective leukocytapheresis in UC therapy. World J Gastroenterol. 2006;12:7568–77. https://dx.doi.org/10.3748/wjg.v12.i47.7568
• 36. Yamamoto T, Umegae S, Matsumoto K. Safety and efficacy of granulocyte and monocyte adsorptive apheresis. World J Gastroenterol. 2006;12:520–5. http://dx.doi.org/10.3748/wjg.v12.i4.520
• 37. Danese S, Fiocchi C. Medical progress. N Engl J Med. 2011;365(1713):25. https://www.nejm.org/doi/abs/10.1056/NEJMra1102942
• 38. Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in UC patients. Gut. 1988;29(3):342–5. https://doi.org/10.1136/gut.29.3.342
• 39. Ford AC, Moayyedi P, Bercik P, et al. Lack of utility of initial symptoms for IBD prediction. Am J Gastroenterol. 2015;110(5):716–24. https://doi.org/10.1038/ajg.2015.117
• 40. Fumery M, Singh S, Dulai PS, et al. Natural history of adult UC in population-based cohorts. Clin Gastroenterol Hepatol. 2018;16(3):343–56. https://doi.org/10.1016/j.cgh.2017.06.016
• 41. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of UC. Autoimmun Rev. 2014;13(4–5):463–6. https://doi.org/10.1016/j.autrev.2014.01.028
• 42. Nikolaus S, Schreiber S. Diagnostics of IBD. Gastroenterology. 2007;133(5):1670–89. https://doi.org/10.1053/j.gastro.2007.09.001
• 43. DeRoche TC, Xiao SY, Liu X. Histological evaluation in UC. Gastroenterol Rep. 2014;2(3):178–92. https://doi.org/10.1093/gastro/gou031
• 44. Magalhaes-Costa MHD, Reis BRD, Chagas VLA, et al. Gastric features in differential diagnosis of UC and Crohn’s. Arq Gastroenterol. 2014;51:276–82. https://doi.org/10.1590/S0004-28032014000300015
• 45. Parente F, Cucino C, Bollani S, et al. Gastric infiltrates in IBD. Am J Gastroenterol. 2000;95(3):705–11. https://doi.org/10.1111/j.1572-0241.2000.01807.x
• 46. D’Haens GR, Geboes K, Peeters M, et al. Patchy inflammation and granulomas in newly diagnosed Crohn’s disease: a prospective endoscopic study. Am J Gastroenterol. 2002;97(4):944–9. https://doi.org/10.1111/j.1572-0241.2002.05628.x
• 47. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4807–12. http://dx.doi.org/10.3748/wjg.v12.i30.4807
• 48. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–34. https://www.nature.com/articles/nature06005
• 49. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621. https://doi.org/10.1146/annurev-immunol-030409-101225
• 50. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–42. https://www.nature.com/articles/nri3661
• 51. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–94. https://doi.org/10.1053/j.gastro.2007.11.059
• 52. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. https://link.springer.com/article/10.1007/s12328-017-0813-5
• 53. Zhou Y, Xu ZZ, He Y, et al. Gut microbiota offers diagnostic biomarkers and therapeutic targets for ulcerative colitis. Clin Transl Gastroenterol. 2020;11(2):e00131. https://doi.org/10.14309/ctg.0000000000000131
• 54. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15(3):382–92. https://doi.org/10.1016/j.chom.2014.02.005
• 55. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780–5. https://doi.org/10.1073/pnas.0706625104
• 56. Rajca S, Grondin V, Louis E, et al. Alterations in intestinal microbiota in ulcerative colitis patients receiving anti-TNF therapy. Gut Microbes. 2014;5(4):579–85. https://doi.org/10.1097/mib.0000000000000036
• 57. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1720–8. https://doi.org/10.1053/j.gastro.2011.01.054
• 58. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–70. https://doi.org/10.1016/S0140-6736(16)32126-2
• 59. Gajendran M, Loganathan P, Catinella AP, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2018;64(12):576–612. https://doi.org/10.1016/j.disamonth.2019.02.004
• 60. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. https://link.springer.com/article/10.1007/s12328-017-0813-5
• 61. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive fecal microbiota transplantation for active ulcerative colitis. JAMA. 2017;318(6):575–84. https://doi.org/10.1016/s0140-6736(17)30182-4
• 62. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative. Gastroenterology. 2021;160(5):1570–83. https://doi.org/10.1053/j.gastro.2020.12.031
• 63. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of UC: Part 2: Current management. J Crohns Colitis. 2017;11(7):769–84. https://doi.org/10.1093/ecco-jcc/jjx009
• 64. Macari M, Balthazar EJ. CT of bowel wall thickening: significance and pitfalls of interpretation. AJR Am J Roentgenol. 2001;176(5):1105–11. https://doi.org/10.2214/ajr.176.5.1761105
• 65. Deepak P, Bruining DH. Radiographical evaluation of ulcerative colitis. Gastroenterol Rep. 2014;2(3):169–77. https://doi.org/10.1093/gastro/gou026
• 66. Pola S, Alloju S, Stanley AJ, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(12):1315–25. https://doi.org/10.1016/j.cgh.2012.07.006
• 67. Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology. 2017;152(2):362–73. https://doi.org/10.1053/j.gastro.2016.10.005
• 68. Ordás I, Rimola J, Rodríguez S, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut. 2013;62(11):1566–72. https://doi.org/10.1136/gutjnl-2012-303240
• 69. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965–90. https://doi.org/10.1016/j.crohns.2012.09.003
• 70. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3):501–23. https://doi.org/10.1038/ajg.2009.727
• 71. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348–54. https://doi.org/10.1016/j.cgh.2015.06.001
• 72. Oussalah A, Laurent V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010;59(8):1056–65. https://doi.org/10.1136/gut.2009.197665
• 73. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1(5375):89. https://doi.org/10.1136/bmj.1.5375.89
• 74. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53. https://doi.org/10.1136/gut.2005.082909
• 75. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A. https://doi.org/10.1155/2005/269076
• 76. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827–51. https://doi.org/10.1016/j.crohns.2013.06.001
• 77. Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–56. https://doi.org/10.1016/j.cgh.2017.06.016
• 78. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94. https://doi.org/10.1053/j.gastro.2011.01.055
• 79. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63(3):423–32. https://doi.org/10.1136/gutjnl-2012-303864
• 80. Stepaniuk P, Bernstein CN, Nugent Z, et al. Characterization of inflammatory bowel disease in elderly patients: A population-based study. Can J Gastroenterol Hepatol. 2015;29(6):327–33. https://doi.org/10.1155%2F2015%2F136960
• 81. Ladd AM, Krevsky B, Curry SB, et al. Demographic and clinical characteristics of a predominantly Hispanic population with inflammatory bowel disease on the US-Mexico border. South Med J. 2016;109(12):792–7. https://doi.org/10.14423/smj.0000000000000571
• 82. Gajendran M, Umapathy C, Loganathan P, et al. Analysis of hospital-based emergency department visits for inflammatory bowel disease in the USA. Dig Dis Sci. 2016;61:389–99. https://link.springer.com/article/10.1007/s10620-015-3895-2
• 83. Liverani E, Scaioli E, Digby RJ, Bellanova M, Chaparro M, Kopylov U, et al. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22(3):1017–33. http://dx.doi.org/10.3748/wjg.v22.i3.1017
• 84. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1245–55.e8. https://doi.org/10.1016/j.cgh.2016.01.015
• 85. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–36. https://doi.org/10.1038/ajg.2015.233
• 86. Ho EY, Cominelli F, Katz J. Ulcerative colitis: what is the optimal treatment goal and how do we achieve it? Curr Treat Options Gastroenterol. 2015;13(1):130–42. https://link.springer.com/article/10.1007/s11938-014-0044-5
• 87. Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory ulcerative colitis. BMJ Open Gastroenterol. 2016;3:e000103. DOI: https://doi.org/10.1136/bmjgast-2016-000103
• 88. Zakko SF, Harris MS, Mahadevan U, et al. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128(3):273–81. https://doi.org/10.1080/00325481.2016.1152876
• 89. Wiggins JB, Rajapakse R. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009;5(10):1279–84. https://doi.org/10.1517/17425250903206996
• 90. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19(2):179–92. https://doi.org/10.1111/j.0269-2813.2004.01827.x
• 91. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63. https://doi.org/10.1016/j.mayocp.2014.07.002
• 92. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. DOI: https://doi.org/10.14309/ajg.0000000000000152
• 93. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ, et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1465–96.e17. https://doi.org/10.1053/j.gastro.2020.01.006
• 94. Taxonera C, Olivares D, Alba C, et al. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–19. https://doi.org/10.1111/apt.17386
• 95. Abu Elainein MA, ElSherefy SS, Yousef NM, ElKady SM, Hamam NG, et al. Efficacy and Safety of Mirikizumab for Ulcerative Colitis: A Systematic Review and Meta-analysis of randomized controlled trials. BMC Gastroenterology. 2025;25:307. https://doi.org/10.1186/s12876-025-03627-2
• 96. Naganuma M, Yokoyama Y, Motoya S, et al. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomized controlled trial. J Gastroenterol. 2020;55(4):390–400. https://link.springer.com/article/10.1007/s00535-019-01651-0
• 97. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400–9. https://doi.org/10.1053/j.gastro.2008.04.023
• 98. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20(3):171–84. https://doi.org/10.1002/jca.20046
• 99. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177. https://doi.org/10.1002/jca.20240
• 100. Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8(8):1361–73. http://dx.doi.org/10.12998/wjcc.v8.i8.1361
• 101. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110–8. https://doi.org/10.1053/j.gastro.2015.03.045